Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced that its US partner IDEAYA Biosciences Inc. (NASDAQ: IDYA) has exercised its option for an exclusive worldwide license for Biocytogen’s IDE034. This potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) represents a significant step forward in the treatment of solid tumors.
IDE034: Targeting Solid Tumors
The high prevalence of B7H3/PTK7 co-expression in solid tumors positions IDE034, which incorporates Biocytogen’s proprietary topoisomerase linker payload technology, as a promising candidate for providing novel treatment options. The drug can be used both as a monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. An Investigational New Drug (IND) filing is anticipated in the US by 2025, pending the completion of ongoing preclinical and IND-enabling studies.
Financial Agreement and Milestones
Under the option and license agreement established in August, Biocytogen is set to receive upfront and option exercise fees, along with additional development and regulatory milestone payments, commercial milestone payments, and royalties on net sales, totaling USD 406.5 million. This includes up to USD 100 million in development and regulatory milestone payments, reflecting the substantial potential of IDE034 in the oncology space.-Fineline Info & Tech
Leave a Reply